Roche/Genentech Keeps Commitment To External Cancer Innovation

Interview: Oncology Partnering’s Don O’Sullivan, Genentech R&D’s Shiva Malek

 
• By Mandy Jackson

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Business consulting with expert help and financial advice tiny person concept
Virtual dealmaking due to COVID-19 did not slow Roche's oncology partnering progress • Source: Shutterstock

More from Deals

More from Business